ALB and non-small cell lung carcinoma: In conclusion, the applications of albumin paclitaxel + bevacizumab and intrapleural perfusion of lobaplatin are effective, and the adverse reactions are tolerable in patients with driver gene-negative NS-NSCLC complicated with malignant pleural effusion.